Why No Generic Cosentyx Yet?
Cosentyx (secukinumab), Novartis's biologic for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lacks generics due to patent protections and regulatory hurdles for biologics. Approved in 2015, it remains under exclusivity with key patents blocking market entry.[1]
When Do Cosentyx Patents Expire?
Core composition-of-matter patents on secukinumab expire in the US around 2028-2030, with method-of-use and formulation patents extending to 2033 or later. Pediatric exclusivity adds six months to some deadlines. Check DrugPatentWatch.com for the latest filings and challenges: DrugPatentWatch - Cosentyx Patents.[2][1]
Biosimilars vs Generics: Why the Difference Matters
Cosentyx can't have true generics—it's a monoclonal antibody biologic, so competitors develop biosimilars, which are highly similar but not identical. Biosimilars face higher FDA hurdles, including clinical trials proving similarity in efficacy and safety, unlike small-molecule generics approved via simple bioequivalence tests.[3]
Which Biosimilars Are in the Pipeline?
Alvotech (AVT04) and Sandoz lead US filings, with FDA interchangeability reviews ongoing as of 2024. Biocon and Intas target Europe, with launches possible post-2025 if patents clear. No approvals yet due to pending litigation from Novartis.[1][4] India and China have earlier versions like Subcutaneous IgG1 from Biocon.
Patent Challenges Holding Them Back
Novartis defends aggressively: Alvotech's lawsuit claims invalidity of certain patents, but settlements or injunctions delay launches. Europe sees similar disputes at the EPO. Successful challenges could accelerate entry by 2-3 years.[2]
How Does This Compare to Other Biologics?
| Drug | Brand Expiry (US) | First Biosimilar Entry |
|------|-------------------|-----------------------|
| Humira | 2023 | 8+ in 2023 |
| Stelara | 2025 | Planned 2025 |
| Cosentyx | 2028+ | Expected 2026-2030 |
| Skyrizi | 2033+ | None yet |
Humira's patents faced heavy challenges, enabling quicker biosimilars. Cosentyx's stronger portfolio slows progress.[1][5]
What Could Speed Up Competition?
Interchangeable designation cuts pharmacy substitution barriers. Price pressures from AbbVie/Amgen rivals like Skyrizi may push settlements. Watch Q1 2025 for Alvotech FDA decisions.[4]
Sources
[1]: DrugPatentWatch.com - Cosentyx
[2]: FDA Orange Book - Secukinumab
[3]: FDA Biosimilars Guidance
[4]: FiercePharma - Cosentyx Biosimilars
[5]: Evaluate Pharma - Biologic Pipeline